			Home About us Contact

Problem Common (problem + common)

Distribution by Scientific Domains

Medical Sciences	50%

Selected Abstracts

Development of a solvent-free, solid-phase in vitro bioassay using vertebrate cells

ENVIRONMENTAL TOXICOLOGY & CHEMISTRY, Issue 5 2006
Stephanie K. Bopp
Abstract Miniaturized bioassays offer many advantages in exploring the toxic potential of chemicals, including small sample volumes and compatibility with high-throughput screening. One problem common to miniaturized systems, however, is the loss of test chemicals because of sorption. The idea of the current study was to use the sorption phenomenon in a positive way. It was found that contaminants sorbed to the growth surface in wells of tissue-culture plates or to the surface of selected sorbent bead materials are available to vertebrate cells growing in direct contact with the contaminant-coated surface. The use of beads provided more flexibility with regard to surface area, materials, and assay format. Biosilon, a bead cell-culture carrier made of polystyrene, was found to be most suitable. It supported cell adherence and allowed the detection of reproducible dose-response curves of an increase in cytochrome CYP1A enzyme activity by sorbed polycyclic aromatic hydrocarbons in the rainbow trout (Oncorhynchus mykiss) liver cell line, RTL-W1. The resulting bead assay provides a miniaturized, solvent-free exposure system. Potential future applications include the coupling to environmental sampling, in which the bead material is used as solid receiving phase before serving as a surface for vertebrate cells to attach and respond. [source]

Estimating flame speeds for use with the BST blast curves

PROCESS SAFETY PROGRESS, Issue 1 2009
Timothy A. Melton
Abstract The Baker-Strehlow-Tang (BST) vapor cloud explosion model is one of the most common methods used to estimate overpressures for the purpose of locating buildings in relation to process units. This model suffers from a problem common to all simplified explosion models: the user is required to pick the "strength" of the explosion using one or more simple parameters. In the BST model, the fuel reactivity, flame expansion, and obstacle density parameters are used to select a flame speed from a limited matrix of possible values. This article presents the Quest Model for estimation of flame speeds (QMEFS), a systematic approach to estimating flame speed that does not rely on the BST categories. It provides for a continuous range of flame speeds that can then be used with the existing BST blast curves to calculate the characteristics of the vapor cloud explosion. The QMEFS approach provides the user with a method for describing a vapor cloud explosion that is more detailed than the BST model, and establishes a more refined system for predicting the consequences of vapor cloud explosions. © 2008 American Institute of Chemical Engineers Process Saf Prog, 2009 [source]

Patient Problems, Advanced Practice Nurse (APN) Interventions, Time and Contacts Among Five Patient Groups

JOURNAL OF NURSING SCHOLARSHIP, Issue 1 2003
Dorothy Brooten
Purpose: To describe patient problems and APN interventions in each of five clinical trials and to establish links among patient problems, APN interventions, APN time and number of contacts, patient outcomes, and health care costs. Design and Methods: Analysis of 333 interaction logs created by APNs during five randomized controlled trials: (a) very low birthweight infants (n=39); (b) women with unplanned cesarean birth (n=61), (c) high-risk pregnancy (n=44), and (d) hysterectomy (n=53); and (e) elders with cardiac medical and surgical diagnoses (n=139). Logs containing recordings of all APN interactions with participants, APN time and type of patient contact were content analyzed with the smallest phrase or sentence representing a "unit." These units were then classified using the Omaha Classification System to determine patient problems and APN interventions. Groups were compared concerning total amount of APN time, number of contacts per patient, and mean length of time per APN contact. All studies were conducted in the United States. Findings: Groups with greater mean APN time and contacts per patient had greater improvements in patients' outcomes and greater health care cost savings. Of the 150,131 APN interventions, surveillance was the predominant APN function in all five patient groups. Health teaching, guidance, and counseling was the second most frequent category of APN intervention in four of the five groups. In all five groups, treatments and procedures accounted for < 1% of total APN interventions. Distribution of patient problems (N=150,131) differed across groups reflecting the health care problems common to the group. Conclusions: Dose of APN time and contacts makes a difference in improving patient outcomes and reducing health care costs. Skills needed by APNs in providing transitional care include well-developed skills in assessing, teaching, counseling, communicating, collaborating, knowing health behaviors, negotiating systems, and having condition-specific knowledge about different patient problems. [source]

L-carnitine supplementation in the dialysis population: Are Australian patients missing out? (Review Article)

NEPHROLOGY, Issue 1 2008
STEPHANIE E REUTER
SUMMARY: It has been widely established that patients with end-stage renal disease undergoing chronic haemodialysis therapy exhibit low endogenous levels of L-carnitine and elevated acylcarnitine levels; however, the clinical implication of this altered carnitine profile is not as clear. It has been suggested that these disturbances in carnitine homeostasis may be associated with a number of clinical problems common in this patient population, including erythropoietin-resistant anaemia, cardiac dysfunction, and dialytic complications such as hypotension, cramps and fatigue. In January 2003, the Centers for Medicare and Medicaid Services (USA) implemented coverage of intravenous L-carnitine for the treatment of erythropoietin-resistant anaemia and/or intradialytic hypotension in patients with low endogenous L-carnitine concentrations. It has been estimated that in the period of 1998,2003, 3.8,7.2% of all haemodialysis patients in the USA received at least one dose of L-carnitine, with 2.7,5.2% of patients receiving at least 3 months of supplementation for one or both of these conditions. The use of L-carnitine within Australia is virtually non-existent, which leads us to the question: Are Australian haemodialysis patients missing out? This review examines the previous research associated with L-carnitine administration to chronic dialysis patients for the treatment of anaemia, cardiac dysfunction, dyslipidaemia and/or dialytic symptoms, and discusses whether supplementation is warranted within the Australian setting. [source]